Predictive association of baseline MRI and ultrasound scores to early methotrexate failure, radiographic erosive progression and MRI erosive progression, ORs (95% CI)
| Univariate | Multivariate | |||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Early methotrexate failure | ||||
| MRI synovitis | 1.04 (0.97 to 1.12) | 0.30 | 0.99 (0.89 to 1.11) | 0.92 |
| MRI tenosynovitis | 1.03 (0.98 to 1.08) | 0.26 | 0.99 (0.92 to 1.07) | 0.78 |
| MRI bone marrow oedema | 1.00 (0.95 to 1.05) | 0.94 | 0.99 (0.93 to 1.06) | 0.81 |
| MRI combined inflammation | 1.00 (1.00 to 1.01) | 0.31 | 1.00 (0.99 to 1.01) | 0.80 |
| Ultrasound grey scale | 1.01 (0.99 to 1.03) | 0.54 | 0.97 (0.94 to 1.00) | 0.09 |
| Ultrasound power Doppler | 1.01 (0.98 to 1.04) | 0.54 | 0.97 (0.92 to 1.01) | 0.14 |
| Radiographic erosive progression | ||||
| MRI synovitis | 1.05 (0.98 to 1.13) | 0.17 | 0.97 (0.88 to 1.08) | 0.64 |
| MRI tenosynovitis | 1.01 (0.97 to 1.06) | 0.57 | 0.97 (0.90 to 1.04) | 0.41 |
| MRI bone marrow oedema | 1.02 (0.98 to 1.07) | 0.31 | 0.96 (0.91 to 1.03) | 0.26 |
| MRI combined inflammation | 1.00 (1.00 to 1.01) | 0.22 | 1.00 (0.99 to 1.00) | 0.32 |
| Ultrasound grey scale | 1.04 (1.02 to 1.06) | <0.001 | 1.05 (1.01 to 1.08) | 0.007 |
| Ultrasound power Doppler | 1.05 (1.02 to 1.08) | 0.001 | 1.06 (1.01 to 1.10) | 0.02 |
| MRI erosive progression | ||||
| MRI synovitis | 1.23 (1.12 to 1.35) | <0.001 | 1.24 (1.06 to 1.45) | 0.007 |
| MRI tenosynovitis | 1.11 (1.05 to 1.18) | <0.001 | 1.09 (1.00 to 1.19) | 0.06 |
| MRI bone marrow oedema | 1.12 (1.06 to 1.18) | <0.001 | 1.10 (1.02 to 1.19) | 0.01 |
| MRI combined inflammation | 1.01 (1.01 to 1.02) | <0.001 | 1.01 (1.00 to 1.02) | 0.002 |
| Ultrasound grey scale | 1.05 (1.02 to 1.08) | <0.001 | 1.08 (1.02 to 1.14) | 0.008 |
| Ultrasound power Doppler | 1.05 (1.02 to 1.08) | 0.001 | 1.04 (0.96 to 1.13) | 0.31 |
Early methotrexate failure: escalation from initial treatment methotrexate monotherapy to triple therapy or bDMARD within the first 6 months of treatment. Radiographic erosive progression: increase ≥2 vdHSS erosion score during follow-up. MRI erosive progression: increase ≥2 RAMRIS erosion score during follow-up. Multivariate model adjusted for clinical model predictors age, gender, SJC, RAI, PGA, CRP, ACPA status and radiographic erosions. Univariate and multivariate associations between the clinical model predictors and the outcomes are shown in online supplemental table S3. P values of <0.05 marked in bold typeface.
ACPA, anti-citrullinated protein antibody ; bDMARD, biological disease-modifying antirheumatic drug; CRP, C reactive protein; PGA, patient global assessment; RAI, Ritchie Articular Index; RAMRIS, rheumatoid arthritis MRI scoring system; SJC, swollen joint count; vdHSS, van der Heijde modified Sharp score.